Trazodone as an Alternative Treatment for Neuroleptic-Associated Akathisia: A Placebo-Controlled, Double-Blind, Clinical Trial. Issue 6 (November 2020)

• Record Type: Journal Article
• Authors: Shams-Alizadeh, Narges; Maroufi, Azad; Asadi, Zahra; Rahmani, Khaled; Hassanzadeh, Kambiz
• Is Part Of: Journal of clinical psychopharmacology. Volume 40:Issue 6(2020)
• Publication Date: 2020-11
• Subjects: akathisia -- trazodone -- antipsychotics; Psychopharmacology -- Periodicals; Psychopharmacology -- Periodicals; Psychopharmacologie -- Périodiques; Psychopharmacology; Periodicals; 615.78
• DOI: 10.1097/JCP.0000000000001286
• Languages: English
• ISSNs: 0271-0749

Abstract

Abstract: Background: Akathisia is a distressing extrapyramidal complication that follows the use of antipsychotic medications. Early treatment of neuroleptic-associated akathisia (NAA) is of great importance because it may lead to poor therapeutic response and ultimately treatment noncompliance. Considering the lack of adequate response of some patients to conventional treatments and the assumption that serotonin might be involved in the pathophysiology of the disease in addition to dopaminergic mechanisms, we aimed to evaluate the effectiveness of trazodone as an antidepressant agent with strong antagonistic effects on serotonin receptors in the treatment of akathisia. Methods: In a double-blind clinical trial, 52 patients receiving antipsychotic medications who were diagnosed to have mild to severe NAA using Barnes Akathisia Rating Scale were treated with trazodone 50 mg daily for 5 days and compared with the placebo control group. Results: Patients receiving trazodone did not show a significant difference compared with the control group in terms of the severity of akathisia symptoms until the third day of the study. In contrast, at the end of the fifth day, there was a significant improvement in objective ( P = 0.01) and subjective ( P = 0.001) symptoms of akathisia and the global clinical assessment of akathisia scale ( P = 0.001). Moreover, there was no clear difference between trazodone and placebo group in terms of adverse effects. Conclusions: Considering the antagonistic effect of trazodone on postsynaptic 5-hydroxytryptamine2A receptors as a possible mechanism of efficacy of this agent in the treatment of NAA, this study suggests that trazodone might be an effective and relatively safe drug. Abstract : Supplemental digital content is available in the text.